Fort Washington Investment Advisors Inc. OH Has $28.18 Million Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Fort Washington Investment Advisors Inc. OH lowered its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 14.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,261,480 shares of the company's stock after selling 206,300 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 1.48% of Progyny worth $28,181,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PGNY. Baillie Gifford & Co. raised its stake in Progyny by 52.2% during the 4th quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after acquiring an additional 456,853 shares in the last quarter. Acuitas Investments LLC acquired a new position in shares of Progyny during the 4th quarter valued at $2,980,000. SBI Securities Co. Ltd. acquired a new position in shares of Progyny during the 4th quarter valued at $74,000. Victory Capital Management Inc. increased its position in shares of Progyny by 79.4% during the 4th quarter. Victory Capital Management Inc. now owns 203,277 shares of the company's stock valued at $3,507,000 after purchasing an additional 89,941 shares during the period. Finally, Edgestream Partners L.P. increased its position in shares of Progyny by 170.1% during the 4th quarter. Edgestream Partners L.P. now owns 186,588 shares of the company's stock valued at $3,219,000 after purchasing an additional 117,506 shares during the period. Institutional investors own 94.93% of the company's stock.

Insider Buying and Selling

In other news, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director now owns 14,112 shares in the company, valued at approximately $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 9.40% of the company's stock.

Progyny Trading Up 0.1%

Shares of NASDAQ PGNY traded up $0.03 during mid-day trading on Monday, reaching $21.06. The company had a trading volume of 879,553 shares, compared to its average volume of 1,707,968. The stock has a market cap of $1.81 billion, a PE ratio of 36.31, a P/E/G ratio of 2.39 and a beta of 1.32. The company has a 50-day moving average price of $21.95 and a two-hundred day moving average price of $20.69. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The company had revenue of $324.04 million during the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.17 earnings per share. On average, research analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Canaccord Genuity Group lowered their price target on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Progyny has an average rating of "Hold" and an average target price of $23.45.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.